title: [SYSTEMIC CYTOKINOTHERAPY, USING BETALEUKIN IN A COMPLEX TREATMENT OF AN ACUTE GASTRODUODENAL ULCER BLEEDING].
abstract: Results of surgical treatment for an acute ulcer gastroduodenal bleeding in 120 patients, ageing 16-75 yrs old, were analyzed. In 20 of them a gastric ulcer was a cause of bleeding, while in 84--a duodenal ulcer, and in 16--a coexistent gastroduodenal ulcer. The bleeding activity was estimated in accordance to J. Forrest classification. In 57 patients (a comparison group) preoperatively and postoperatively a complex of a standard basal conservative therapy without immunocorrection was conducted, and in 63 (the main group)--a systemic cytokinotherapy (SCKTH), using betaleukin, was applied postoperatively additionally in a complex of therapy. A content of CD3+, CD4+, CD8+, CD19+, IgA, IgM, IgG was estimated in dynamics, as well as circulating immune complexes, phagocytic index, phagocytic number. There was established, that a dysbalance depth in the immune status have had depended upon the blood loss severity. The SCKTH application is pathogenetically substantiated, it promotes the immune status normalization, as well as a more favorable course of postoperative period and the results of treatment improvement.
authors: J N
authors: JN
authors: Gadjiyev
authors: V A
authors: VA
authors: Allakhverdiyev
authors: S V
authors: SV
authors: Sushkov
authors: N J
authors: NJ
authors: Gadjiyev
authors: V I
authors: VI
authors: Yagubova
authors: E V
authors: EV
authors: Lavinskaya
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000936:Antigen-Antibody Complex / Q000097:blood; D015703:Antigens, CD / Q000276:immunology; D016022:Case-Control Studies; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology / Q000601:surgery; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D007155:Immunologic Factors / Q000627:therapeutic use*; D016130:Immunophenotyping; D053583:Interleukin-1beta / Q000627:therapeutic use*; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010437:Peptic Ulcer / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000601:surgery; D011994:Recombinant Proteins / Q000627:therapeutic use; D012720:Severity of Illness Index; D013276:Stomach Ulcer / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000601:surgery; D016896:Treatment Outcome
chemical_list: D000936:Antigen-Antibody Complex; D015703:Antigens, CD; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007155:Immunologic Factors; D053583:Interleukin-1beta; D011994:Recombinant Proteins